Abstract:Inherited retinal dystrophies (IRDs) display remarkable genetic heterogeneity, with over 300 retinal disease genes mapped and/or identified. Profound vision loss and blindness, often from birth, is a common occurrence in these clinically heterogeneous disease conditions. The therapeutic options for IRDs are currently very limited but recent advancements in understanding mechanisms of retinal degeneration and technological progress paved the way towards development of novel therapies. Much progress has been made in moving from gene discovery to gene therapy. However, the genetic heterogeneity of IRDs represents a significant challenge for development of gene therapy. Many studies from our group have demonstrated that the survival of cones (responsible for diurnal and high‐resolution vision) depends on the presence of rods (responsible for vision at low light levels) that secrete a diffusible trophic factor identified as rod‐derived cone viability factor (RdCVF). The discovery of RdCVF, of its receptor and mechanism of action, and the demonstration of its mutation‐independent therapeutic potential in several animal models of IRDs paved the way to the development (with the start‐up company Sparing Vision) of RdCVF neuroprotective gene therapy that entered in clinical trial in 2023. IRDs destroy photoreceptors but leave intact and functional a significant number of inner retinal cells. Using viral vectors, light‐sensitive microbial opsins can be expressed in these remaining cells, making possible their conversion into ‘artificial photoreceptors’. Our group in Paris, together with Botond Roska (IOB, Basel) and the biotech company GenSight, demonstrated that this technology, named optogenetics, can restore vision in secondary retinal neurons which can survive years after the degeneration of photoreceptors. Our groups established the foundation for the first‐in‐man clinical trial (NCT03326336) with the photoactivatable optogene ChrimsonR (developed by Ed Boyen at MIT) delivered in the eye via adeno‐associated viral vectors and electronic goggles to intensify the light and provide adaptation. We demonstrated ( Nat Med 2021 ) that optogenetics is a remarkably effective way to restore partial vision and provide useful vision restoration in blind people. Gene‐independent approaches such as neuroprotection and optogenetics would allow for the treatment of a broad spectrum of retinal dystrophies, even at advanced stages of disease, giving hope for vision rescue and vision restoration to approximately 2 million people with IRDs worldwide.

Multidisciplinary Approaches in the Treatment of Retinal Degenerative Diseases: A Review

Adaptive Interfacial Materials and Implants for Visual Restoration

Stem/progenitor Cell-Based Transplantation for Retinal Degeneration: a Review of Clinical Trials.

Multifunctional nano-in-micro delivery systems for targeted therapy in fundus neovascularization diseases

Recent Developments of Neuroprotective Agents for Degenerative Retinal Disorders.

Progress in Photoreceptor Replacement Therapy for Retinal Degenerative Diseases

Towards Stem/Progenitor Cell-Based Therapies for Retinal Degeneration

Retinal degeneration: molecular mechanisms and therapeutic strategies

Progress of stem/progenitor cell-based therapy for retinal degeneration

Bioengineering strategies for restoring vision

Next generation therapeutics for retinal neurodegenerative diseases

Developing Cell-Based Therapies for RPE-Associated Degenerative Eye Diseases

Regeneration of the Retina Using Pluripotent Stem Cells: A Comprehensive Review

Recent Progress in Photoreceptor Cell-Based Therapy for Degenerative Retinal Disease

Stem/progenitor cells and biodegradable scaffolds in the treatment of retinal degenerative diseases.

Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases

Recent advances in the treatment and delivery system of diabetic retinopathy

Developing gene‐independent approaches for retinal dystrophies

Research Progress of Stem Cell-Derived RPE Cell Transplantation Therapy for Retinal Degenerative Diseases

Advances in Ophthalmic Optogenetics: Approaches and Applications

Retinal delivery of nanotherapeutics in a model of inherited retinal dystrophy